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Case Review
A 54- year- old female presented with 1 week history of 
self- discovered left breast lump in August 2010. The lump 
was painless with no skin or nipple changes and no axil-
lary swelling. She was post- menopausal with three grown 
children. She was a lifelong non- smoker and did not take 
alcohol. There was no family history of cancer. Initial 
mammography and left breast ultrasound revealed a 1.4 
× 0.9 cm irregular mass in the left upper outer quadrant. 
Biopsy of the lesion confirmed invasive lobular carcinoma 
that was estrogen receptor (ER) and progesterone receptor 
(PR) positive and human epidermal growth factor-2 
(HER2) equivocal (2+), for which, HER2 Fluorescence 
in situ hybridization was negative. Bone scan showed 
two areas of increased uptake in the proximal and distal 
portion of the sternum suggestive of metastases. She had 
no other sites of metastases. In view of the oligometastatic 
disease, the patient was treated aggressively with modified 
radical mastectomy followed by adjuvant chemotherapy 
and radiotherapy. She was then started on endocrine 
therapy.
4 years later, she presented with increased bone pain which 
on CT scan and bone scan confirmed extensive bone 
metastases but no other sites of disease. She received palli-
ative radiotherapy to the spine and treatment changed to 
everolimus and fulvestrant with denosumab. In 2016, she 
had skin nodules which were confirmed on biopsy to be 
invasive lobular carcinoma (ER/PR positive and HER2 
negative). Therapy changed to single agent capecitabine.
7 years after her initial diagnosis, the patient presented with 
abdominal fullness and hematuria. CT scan now showed 
extensive bladder wall thickening (Figure  1), new onset 
ascites and pleural effusion. Cystoscopy confirmed multiple 
tumor deposits in the bladder. Unfortunately, no sample 
was submitted for histology. Bilateral ureteric stents were 
inserted, ascitic and pleural drains inserted and patient 
regimen was changed. Her ECOG performance status 
remained one and received further lines of chemotherapy 
including gemcitabine and carboplatin, eribulin and nab- 
paclitaxel. 9 months after diagnosis of bladder metastases, 
her condition deteriorated and she was transitioned to 
best supportive care and she eventually succumbed to her 
illness.
DisCUssioN
While breast cancer is the most common malignancy in 
females, metastases to the urinary bladder are extremely 
rare. Approximately, 54 cases have been reported in litera-
ture to date.1 In several autopsy studies, the rate of bladder 
metastases from breast cancer range from 1.2 to 7%.1 
Bladder metastases more commonly arise from tumors in 
the pelvic region such as the cervix, rectum and prostate.2 
Breast cancer more commonly spreads to the liver, lung and 
bone.2,3
As in our patient, the most common histological subtype 
associated with bladder metastases is invasive lobular carci-
noma even though invasive ductal carcinoma is the most 
common histological subtype of primary breast cancer.1,2,4 
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abstRaCt
Breast cancer is the most common cancer in women globally as well as in Kenya. The most common sites of metastases 
reported include the bones, liver and lung. Metastasis to the urinary bladder is relatively uncommon with only a few 
case reports in literature. It can therefore be easily overlooked as a cause of hematuria in these patients. We describe 
a rare case of a patient with breast cancer who presented with urinary bladder metastasis as a late complication of her 
illness.
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The postulated mechanisms of spread from the breast primary 
to the bladder include hematogenous spread of viable tumor 
emboli through pulmonary circulation without establishing lung 
metastases with subsequent bladder involvement. It is postulated 
that because invasive lobular carcinoma loses e- cadherin, this 
leads to more metastases as cell–cell adhesion is lost. In addition, 
lobular carcinoma being a serosal type cancer is likely to spread 
into the gastrointestinal system and genitourinary system.2
The most common presentation of patients with bladder metas-
tases as with our case is gross hematuria. Other signs and symp-
toms include urinary frequency, incontinence, dysuria, lower 
abdominal pain and back pain.5–7 There is a recent report of 
an asymptomatic patient found to have bladder metastases on 
routine follow up CT scan 2 years after initial therapy for breast 
cancer.8
Imaging for patients suspected to have bladder metastases include 
bladder ultrasound, CT scan or MRI of the pelvis. Typically, 
bladder wall thickening is seen with or without hydronephrosis 
and hydroureter. Cystoscopy is mandatory for confirming the 
diagnosis. In majority of the case reports, cystoscopy revealed 
large tumor deposits as was found in our patient described 
above.9 Histology and immunohistochemistry including 
staining for ER and PR as well as HER2 is crucial in confirming 
the primary tumor from breast and to exclude a primary bladder 
cancer. Discordance in hormonal status in primary and meta-
static sites has however been reported to be around 24 and 39%.1 
More recent publications have not found additional information 
to that reported in previously cited literature.3,4
Therapies include local resection of the bladder tumor during 
cystoscopy, palliative radiotherapy and systemic therapy. Ureteric 
stenting may also be indicated for those with hydronephrosis and 
renal dysfunction. It has been reported that survival is short after 
diagnosis of bladder metastases.10
CoNClUsioN
Metastases to urinary bladder from breast cancer is a rare 
occurrence but should be considered for breast cancer patients 
presenting with urinary symptoms, in particular hematuria.
leaNiNg poiNts
1. Although rare, urinary bladder metastasis from breast 
cancer should be considered for patients presenting with 
urinary symptoms, in particular hematuria.
2. The most common histological subtype associated with 
bladder metastases is invasive lobular carcinoma.
3. Cystoscopy is recommended for patients with invasive 
lobular carcinoma presenting with hematuria to exclude 
bladder metastasis.
Figure 1.  A 54- year- old female with breast cancer presenting 
with hematuria. Axial (a) and sagittal (b) CT images of the of 
the pelvis show enhancing irregular bladder wall thickening 
(arrows).
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